Advantages

- High Organ Specificity & Low Toxicity: Uses lipid nanoparticles (LNP) targeting lung vascular endothelial receptors to minimize systemic side effects.
- Multi-Faceted Aggravation Control: Local anti-inflammatory and anti-thrombotic actions simultaneously suppress vasculitis and micro thrombosis.
- Proven Respiratory Function Protection: Significantly prevents drops in oxygen saturation SpO2 and dramatically improves survival rates.
- Broad Indication Potential: Expandable to intractable vasculitis, interstitial pneumonia, and other cardiopulmonary conditions.

Current Stage and Key Data

In vivo Proof of Concept (PoC) established using aged severe infection mouse models.
- Biodistribution Data: Demonstrated marked lung-specific accumulation 2 hours post-intravenous administration compared to other organs (liver, spleen, heart, kidney).
- Respiratory Function & Survival Rate Data: Late-stage administration suppressed SpO2 reduction and achieved a 100% survival (2.5x102 pfu viral load).
- Pathological Data: Markedly reduced the formation of CD41-positive intravascular pulmonary thrombi.

Partnaring Model

Joint R&D, technology licensing, joint patenting, and commercialization partnerships..
- Potential Partners: Pharma companies with nanoparticle/LNP platforms or DDS pipelines targeting respiratory, cardiovascular, or infectious diseases.

Background and Technology

Advanced viral infections like COVID-19 trigger severe pulmonary vasculitis, thrombosis, and fatal pneumonia. Current antivirals target early stages, leaving limited options for late-phase patients with severe respiratory failure. While potent anti-inflammatory and anti-thrombotic small molecules exist, their clinical use is restricted by a narrow therapeutic window due to systemic toxicity and weight loss.

Principal Investigator

Kyoko HIDA (Graduate School of Dental Medicine, Hokkaido University)
Hideyoshi HARASHIMA（Faculty of Pharmaceutical Sciences, Hokkaido University）

Patents and Publications

Patent pending